AMRX Strangle Strategy
AMRX (Amneal Pharmaceuticals, Inc.), in the Healthcare sector, (Drug Manufacturers - Specialty & Generic industry), listed on NASDAQ.
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products with focus on central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers Emverm, a chewable tablet for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; Rytary to treat Parkinson's disease; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs.
AMRX (Amneal Pharmaceuticals, Inc.) trades in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a market capitalization of approximately $3.95B, a trailing P/E of 33.31, a beta of 1.32 versus the broader market, a 52-week range of 7.02-15.42, average daily share volume of 1.9M, a public-listing history dating back to 2018, approximately 8K full-time employees. These structural characteristics shape how AMRX stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.32 indicates AMRX has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a strangle on AMRX?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current AMRX snapshot
As of May 15, 2026, spot at $11.95, ATM IV 51.20%, IV rank 18.14%, expected move 14.68%. The strangle on AMRX below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on AMRX specifically: AMRX IV at 51.20% is on the cheap side of its 1-year range, which favors premium-buying structures like a AMRX strangle, with a market-implied 1-standard-deviation move of approximately 14.68% (roughly $1.75 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated AMRX expiries trade a higher absolute premium for lower per-day decay. Position sizing on AMRX should anchor to the underlying notional of $11.95 per share and to the trader's directional view on AMRX stock.
AMRX strangle setup
The AMRX strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With AMRX near $11.95, the first option leg uses a $12.55 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed AMRX chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 AMRX shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $12.55 | N/A |
| Buy 1 | Put | $11.35 | N/A |
AMRX strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
AMRX strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on AMRX. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on AMRX
Strangles on AMRX are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the AMRX chain.
AMRX thesis for this strangle
The market-implied 1-standard-deviation range for AMRX extends from approximately $10.20 on the downside to $13.70 on the upside. A AMRX long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current AMRX IV rank near 18.14% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on AMRX at 51.20%. As a Healthcare name, AMRX options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to AMRX-specific events.
AMRX strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. AMRX positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move AMRX alongside the broader basket even when AMRX-specific fundamentals are unchanged. Always rebuild the position from current AMRX chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on AMRX?
- A strangle on AMRX is the strangle strategy applied to AMRX (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With AMRX stock trading near $11.95, the strikes shown on this page are snapped to the nearest listed AMRX chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are AMRX strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the AMRX strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 51.20%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a AMRX strangle?
- The breakeven for the AMRX strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current AMRX market-implied 1-standard-deviation expected move is approximately 14.68%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on AMRX?
- Strangles on AMRX are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the AMRX chain.
- How does current AMRX implied volatility affect this strangle?
- AMRX ATM IV is at 51.20% with IV rank near 18.14%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.